Janssen Research & Development, LLC
Clinical trials sponsored by Janssen Research & Development, LLC, explained in plain language.
A pharmaceutical R&D arm of Johnson & Johnson, developing drugs across multiple therapeutic areas.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Tiny trial tracks leukemia Drug's journey through the body Results expected Sep 2026 (estimated)
- Could pausing hormone therapy ease hot flashes without hurting cancer control? Results expected Oct 2026 (estimated)
- New pill aims to cut stroke risk without the bleeding worry Results expected Oct 2026 (estimated)
- New combo therapy targets tough leukemia mutations Results expected Oct 2026 (estimated)
- New hope for tough blood cancers? early trial of JNJ-89853413 begins Results expected Nov 2026 (estimated)
-
Eczema drug trial halted early – what we know
Disease control Stopped earlyThis study tested an experimental drug called JNJ-95475939 in 256 adults with moderate to severe atopic dermatitis (eczema). The goal was to see if the drug could improve skin symptoms like redness, itching, and scaling better than a placebo. The trial was stopped early, so final…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Promising depression relapse prevention drug study halted early
Disease control Stopped earlyThis study tested whether adding the drug aticaprant to standard antidepressants could prevent depression from returning in people with major depressive disorder who also experience a loss of interest or pleasure (anhedonia). The study enrolled 47 adults who had responded well to…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Depression drug aticaprant safety trial halted early
Disease control Stopped earlyThis study tested the long-term safety of a drug called aticaprant when added to a standard antidepressant for adults with major depression. The trial planned to enroll 871 people but was terminated early, so the full safety and effectiveness data are not available. Researchers w…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Alzheimer's Tau-Targeting antibody trial halted midway
Disease control Stopped earlyThis study tested an experimental antibody called JNJ-63733657 in 523 people with early Alzheimer's disease. The antibody aims to clear tau protein clumps in the brain, which are linked to cognitive decline. Participants received either the antibody or a placebo by IV infusion. T…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Depression drug trial halted: aticaprant fails to show promise for anhedonia
Symptom relief Stopped earlyThis study tested whether adding aticaprant to standard antidepressants could help people with major depression who still feel no pleasure (anhedonia). The trial was stopped early after enrolling only 101 participants. No results are available, so it is unknown if aticaprant work…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC